Acumen Pharmaceuticals, Inc. Proceeds from Sale and Maturity of Marketable Securities
Acumen Pharmaceuticals, Inc. (ABOS) reported Proceeds from Sale and Maturity of Marketable Securities of $53.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $26.00M, a 37.35% decline year-over-year.
- Acumen Pharmaceuticals, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $27.02M, a 57.67% decline year-over-year.
- Acumen Pharmaceuticals, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $26.25M, a 41.36% decline year-over-year.
- Acumen Pharmaceuticals, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $40.51M, a 54.18% decline year-over-year.
- Acumen Pharmaceuticals, Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $172.08M, a 21.34% decline from fiscal 2024.
- Acumen Pharmaceuticals, Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $218.77M, a 177.00% increase from fiscal 2023.
- Acumen Pharmaceuticals, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $78.98M, a 2.32% decline from fiscal 2022.
- Acumen Pharmaceuticals, Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $80.86M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $53.02M 10-Q · filed 2026-08-12 | $79.27M derived: sum of 3 quarters · filed 2026-08-12 | $119.78M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $27.02M 10-Q · filed 2026-05-12 | $53.27M derived: sum of 2 quarters · filed 2026-05-12 | $93.78M derived: sum of 3 quarters · filed 2026-05-12 | $135.28M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $26.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $66.76M derived: sum of 2 quarters · filed 2026-03-26 | $108.26M derived: sum of 3 quarters · filed 2026-08-12 | $172.08M 10-K · filed 2026-03-26 |
| 2025-09-30 | $40.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $82.01M derived: sum of 2 quarters · filed 2026-08-12 | $145.83M 10-Q · filed 2025-11-12 | $190.59M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $41.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $105.32M 10-Q · filed 2026-08-12 | $150.08M derived: sum of 3 quarters · filed 2026-08-12 | $238.49M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $63.82M 10-Q · filed 2026-05-12 | $108.58M derived: sum of 2 quarters · filed 2026-05-12 | $196.99M derived: sum of 3 quarters · filed 2026-05-12 | $246.49M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $44.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $133.17M derived: sum of 2 quarters · filed 2026-03-26 | $182.67M derived: sum of 3 quarters · filed 2026-03-26 | $218.77M 10-K · filed 2026-03-26 |
| 2024-09-30 | $88.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $137.91M derived: sum of 2 quarters · filed 2025-11-12 | $174.01M 10-Q · filed 2025-11-12 | $197.00M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $49.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $85.61M 10-Q · filed 2025-08-12 | $108.59M derived: sum of 3 quarters · filed 2025-08-12 | $143.32M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $36.10M 10-Q · filed 2025-05-13 | $59.08M derived: sum of 2 quarters · filed 2025-05-13 | $93.81M derived: sum of 3 quarters · filed 2025-05-13 | $104.88M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $22.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $57.71M derived: sum of 2 quarters · filed 2025-03-27 | $68.78M derived: sum of 3 quarters · filed 2025-03-27 | $78.98M 10-K · filed 2025-03-27 |
| 2023-09-30 | $34.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $45.79M derived: sum of 2 quarters · filed 2024-11-12 | $56.00M 10-Q · filed 2024-11-12 | $65.00M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $11.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $21.27M 10-Q · filed 2024-08-13 | $30.27M derived: sum of 3 quarters · filed 2024-08-13 | $86.27M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $10.20M 10-Q · filed 2024-05-14 | $19.20M derived: sum of 2 quarters · filed 2024-05-14 | $75.20M derived: sum of 3 quarters · filed 2024-05-14 | $87.06M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $65.00M derived: sum of 2 quarters · filed 2024-03-26 | $76.86M derived: sum of 3 quarters · filed 2024-03-26 | $80.86M 10-K · filed 2024-03-26 |
| 2022-09-30 | $56.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $67.86M derived: sum of 2 quarters · filed 2023-11-13 | $71.86M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $11.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $15.86M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $4.00M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |